Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four separate medications: 1. **Recombinant growth hormone (somatropin)**: A synthetic form of human growth hormone that stimulates tissue growth, linear growth (height), and regulates protein, carbohydrate, lipid, and mineral metabolism. It's used to treat various growth disorders in children and adults. 2. **Amitriptyline**: A tricyclic antidepressant that works by increasing levels of serotonin and norepinephrine in the brain. 3. **Fluoxetine**: A selective serotonin reuptake inhibitor (SSRI) antidepressant that increases serotonin levels in the brain. 4. **Tramadol**: An opioid pain medication that works by binding to opioid receptors and inhibiting the reuptake of serotonin and norepinephrine. This specific combination is not a standard therapeutic regimen and would be highly unusual as these medications have different therapeutic purposes and potential serious interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant growth hormone + amitriptyline + fluoxetine + tramadol.